US approval of bone graft ‘game changer’

Press/Media: Research


US regulatory clearance for a “game-changing” bone graft substitute has been hailed a key milestone for Aberdeen University spinout Sirakoss.

The Foresterhill-based firm said Food and Drug Administration (FDA) approval for its new-type, synthetic bone graft – developed for procedures such as spine and bone trauma surgery – paved the way for commercialisation plans.

Iain Gibson, co-founder and director of research and development at Sirakoss, and also professor of acellular regenerative medicine at Aberdeen University, said: “Our Osteo3 ZP Putty has demonstrated excellent pre-clinical performance in models of spinal fusion and trauma repair.

Period19 Jun 2020

Media coverage


Media coverage


  • Sirakoss